Money Raised Year To Date - July 1, 2002

Editor Say "Festo" to a member of the general public and he's likely to think of pasta, red wine and merriment. Say it to almost any of the competing parties in biotechnology, though, and your listener is likely to groan louder than the victim of a bad pun. For industry leaders, the word most immediately denotes not an Italian party, or "festa," but a company Festo Corp., the subject last month of a U.S. Supreme Court decision in the closely watched patent case filed in 1988 against Shoketsu

I. MODIFIED AGREEMENTS Biotech Co.* (Country; Symbol) Pharma Co. (Country) Change from original agreement Terms/Details (Date) Axiom Biotechnologies Inc.* UCB SA (Belgium) Extended collaboration to discover drugs for the treatment of allergic rhinitis Terms include an up-front payment, research support, milestone payments and bonuses; the one-year contract is extendable for a second year (4/2) ChemCodes Inc.* GlaxoSmithKline plc (UK) Expanded technology license agreement The

Biotech Co.* (Country; Symbol) Pharma Co. (Country) Product Terms/Details (Date) Cepheid Inc. (CPHD) Izasa SA (Spain) Cepheid Smart Cycler system Multiyear distribution agreement to market the Cepheid Smart Cycler system, accessories and disposable reaction tubes in Spain, Portugal, Italy, Austria, France, the Netherlands and the UK; Izasa will provide marketing sales and service support (5/28) Guilford Pharmaceuticals Inc. (GLFD) Orphan Australia Pt. Ltd. (Australia

Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date) Abaris Pharma Inc.* (subsidiary of Corus Pharma Inc.) BattellePharma Inc. Development and licensing agreement in which Abaris will use BattellePharma's Mystic inhalation technology for the delivery of its lidocaine drug to treat asthma BattellePharma will receive an up-front payment, program milestone payments and royalties on product revenues (6/11) Accelrys Inc. (subsidiary of Pharmacopeia

Money Raised Year To Date

Staff Writer Every start-up biotech company dreams about breakthrough product approvals, positive cash flows and becoming global. It takes a good product and good science to attain the first two. But for a company to become truly global, it also takes a good head. There are things to think about, such as cultural differences, tax advantages and market sizes, not to mention capital. "The biggest danger is getting overextended," said James Mullen, president and CEO of Cambridge, Mass.-based

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE Biogen Inc. (BGEN) Amevive Alefacept; novel immuno-modulatory agent that selectively targets the CD45RO+ subset of T cells Psoriasis The Dermatologic and Ophthalmic Ophthalmic Drugs Advisory Committee recommended approval of Amevive (5/23) CANCER Antigenics Inc. (AGEN) Oncophage Vaccine; uses heat shock proteins to activate cellular immune responses Renal cell carcinoma FDA granted orphan drug status

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE KS Biomedix Holdings plc (UK; LSE:KSB) KSB302 A small molecule that modulates biochemical imbalances Rheumatoid arthritis Company said it is dropping the product after a Phase IIb study failed to reach its primary end-point (5/29**) CANCER GPC Biotech AG (Germany; FSE:GPC) Bryostatin-1 Linked to the modulation of protein kinase C Esophageal cancer European Commission granted orphan medicinal product

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE Abgenix Inc. (ABGX) ABX-IL8 Monoclonal antibody that blocks interleukin-8 Psoriasis ABX-IL8 failed in a Phase IIb trial to meet its primary endpoint of improvement in PASI scores (5/14) Celltech plc (UK; NYSE:CLL) CDP 870 Antibody drug administered by monthly injection Crohn's disease A pilot study with 92 patients showed that 47% of patients treated with a single infusion achieved

Money Raised Year To Date

Money Raised Year To Date

I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $288.979M Company Location Date Amt. (M) Details Advion BioSciences Inc. Ithaca, N.Y. 5/7 $15 Advion raised $15M in a Series B financing round led by Skyline Ventures and Perseus-Soros BioPharmaceutical Fund; other investors were Polaris Venture Partners and Soros Private Equity Partners Agennix Inc. Houston 5/30 $20 Agennix raised $20M in a financing led by Gordon Cain, the company's chairman Arriva Pharmaceuticals Inc. Alameda, Calif. 5/7 $28